The first European company is in 25th place – Denmark’s Novo Nordisk, famed for its manufacture of Ozempic ... Germany’s car ...

China has recovered slightly from last year ... up from just 33% last year. Earlier in November, Novo Nordisk's Wegovy weight ...

The global GLP-1 analogues market size was assessed at USD 46.70 billion in 2024. The market is expected to flourish and grow from USD 56.62 billion in 2025 to USD 322.85 billion by 2034, denoting a ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

Prior to the election, Biden was eager to talk about the existential threat that the president-elect posed to American democracy and the nightmarish future he said would follow if Trump ever returned ...

Novo Nordisk rose after the Danish giant launched its Wegovy weight-loss product in China. Merck reported promising trial results for a new, easier-to-administer formulation of its blockbuster cancer ...

Novo Nordisk’s blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles ...

As China rises to second place, next only to the U.S., for innovative new drugs, a new report by Clarivate – A Decade of Innovation, A Decade to Come – outlines key policy reforms and regulatory, R&D ...

With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, ...

Novo Nordisk has launched Wegovy – its popular weight loss treatment – in China. China, with a population of 1.4 billion, has ...

Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...